Texas A&M Health Science Center
2121 W. Holcombe Blvd
Institute of Biosciences and Technology
Houston, TX 77030
United Stateshttps://ibt.tamu.edu/centers/translational-cancer-research/stephan-lab/folder/index.htmlcite this facility
Clifford Stephan
Last Updated: 06/23/2023
The Microphysiological Leads Optimization and Toxicity Screening facility (MLOTS) supports lead optimization programs and has established a roster of medium-throughput microphysiologic screening platforms including tissue- and tumor-on-a-chip platforms, organoid, and spheroid culture systems that will be used to evaluate the efficacy and toxicity of new lead compounds and drug combinations.
The pharmaceutical industry has recognized the importance of implementing a “fail early” screening strategy early in the drug development process by adopting advanced physiological screening platforms and predictive in vitro toxicology testing. MLOTS supports a "fail early" approach as a lead optimization strategy by providing the resources to identify. toxic liabilities in lead series molecules before entering pre-clinical or clinical testing. MLOTS can evaluate NME for cardiovascular, neuro, or liver toxicity relative to reference standards using in vitro screening platforms.
Services are offerred outside of Texas A&M Health Science Center
Consulting is offerred outside of Texas A&M Health Science Center
